Shenzhen Beimei Pharmaceutical Co., Ltd. has successfully obtained the medicine production license B certificate of desloratadine oral solution.

Desloratadine oral solution is one more product independently developed by Beimei R & D Center since its establishment. In June 2022, Desloratadine oral solution successfully completed pilot scale-up and process validation production in Huayi Pharmaceutical Technology Co., Ltd. (CMO company), declared to Guangdong Food and Drug Administration, and obtained the medicine production license B certificate for this product.

With the progress of R&D, it is believed that in the future, more and more products of Beimei will be developed rapidly.

About Beimei Pharmaceutical

Beimei pharmaceutical focuses on the field of pediatric prescription medicines, headquartered in Shenzhen, China, incorporating R&D, global licensing, manufacture, marketing and distribution, and has more than 30 pediatric products in its portfolio and pipeline, covering the respiratory system, anti-infection (antibacterial), nervous system, digestive system, endocrinology, ENT and other fields.

Beimei Pharmaceutical has established long-term partnerships with companies such as Hetero, Cipla, EMP, Deva, Dr Reddy, LTS, MedPharma, Synthon, NTC, etc., and completed over 100 million RMB series A and series B/B+ financing, which will further support Beimei to be a pioneer in Chinese pediatric field to meet the clinically unmet demand and provide Chinese pediatric patients with products that are with high-quality, good tasting and can be accurately administrated.